Brexpiprazole — Rexulti — is aripiprazole's close cousin. Same partial agonist class. Same mechanism family. Different tuning. Brexpiprazole has lower intrinsic D2 activity than aripiprazole — closer to an antagonist on the partial-agonism spectrum. That tuning difference produces clinically distinct side effects.
- Class
- Third-generation antipsychotic / dopamine partial agonist
- Mechanism
- D2 partial agonist (lower intrinsic activity than aripiprazole — closer to antagonist) + 5-HT1A partial agonist + 5-HT2A antagonist
- Typical dose
- Schizophrenia 2-4 mg/day; MDD adjunct 1-3 mg; agitation in Alzheimer's dementia (recently approved) 0.5-2 mg
- Half-life
- ~91 hours
- FDA indications
- Schizophrenia, MDD adjunct, agitation associated with Alzheimer's dementia
- Key adverse effects
- Less akathisia than aripiprazole, more sedation/weight gain, akathisia, restlessness, impulse control disorders (rare)
Black box: Increased mortality in elderly patients with dementia-related psychosis (note: now FDA-approved for Alzheimer's agitation with risk-benefit weighed)
Lower intrinsic D2 activity than aripiprazole — less akathisia but more sedation. Recently approved for Alzheimer's dementia agitation (a previously unmet need). Higher cost limits use vs. aripiprazole when no specific differentiator.
Less akathisia than aripiprazole. More sedation. More weight gain. The patient who responded to aripiprazole but couldn't tolerate the akathisia is often the patient who benefits from brexpiprazole. The patient who was sleepy on quetiapine and now needs something cleaner metabolically might also be a candidate.
Brexpiprazole is a D2 partial agonist refined from aripiprazole — lower intrinsic activity at D2, intended for less akathisia and activation.
Mechanism note: Brexpiprazole is aripiprazole tuned for less akathisia and activation; its distinctive niche is the FDA-approved indication for agitation in Alzheimer's dementia.
FDA indications: schizophrenia, MDD adjunct, and — recently — agitation associated with Alzheimer's dementia. The Alzheimer's agitation indication is notable: this is one of the few antipsychotics with a specific FDA approval for dementia-related agitation, against the backdrop of the black-box warning about mortality in elderly patients with dementia-related psychosis. The risk-benefit must be weighed individually, and behavioral interventions remain first-line, but brexpiprazole offers an FDA-supported pharmacologic option for severe cases.
Other side effects parallel the aripiprazole class — impulse control disorders (rare but emergent), modest metabolic effects, mild EPS at higher doses. Drug interactions via CYP2D6 and 3A4 are clinically relevant.
Cost is the practical constraint that limits widespread use. Brexpiprazole is brand-only and expensive. For the patient who needs the specific tuning — partial agonism with less akathisia, more sedation — it can be worth the cost. For most other situations, aripiprazole or other SGAs are the starting point.
- Cost
- Brand-only Rexulti: ~$1,500/month.
- Generic status
- No generic anticipated near-term.
- Formulary typical
- Specialty tier with PA universal.
- Access friction
- PA documenting prior failed agents typical. Recent Alzheimer's agitation approval has expanded coverage in some plans.
Prescriber tip: For aripiprazole akathisia, brexpiprazole is the natural switch — PA usually goes through on that rationale. Otsuka co-pay programs for commercial patients.